This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
GSKNegative Net Change PBYIPositive Net Change CTMXPositive Net Change CSTLPositive Net Change
biotechs
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
by Zacks Equity Research
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.
REGNPositive Net Change VNDANegative Net Change RAREPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs
by Zacks Equity Research
ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.
ABBVPositive Net Change PBYIPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
by Zacks Equity Research
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.
BMYPositive Net Change MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.
JNJPositive Net Change PBYIPositive Net Change VNDANegative Net Change CSTLPositive Net Change
biotechs
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
by Zacks Equity Research
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
VNDANegative Net Change CTMXPositive Net Change KODPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
by Sundeep Ganoria
The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential.
RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
by Zacks Equity Research
The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.
CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change ARQTPositive Net Change
biotechs medical
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
by Zacks Equity Research
Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.
MESOPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
by Zacks Equity Research
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.
CAPRNegative Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Neumora Stock Hits Record Low on Depression Drug Study Failure
by Zacks Equity Research
NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.
CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change NMRAPositive Net Change
biotechs medical
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
by Zacks Equity Research
The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.
INOPositive Net Change CTMXPositive Net Change CSTLPositive Net Change PGENPositive Net Change
biotechs medical
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
by Zacks Equity Research
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.
AZNPositive Net Change SPRONegative Net Change CSTLPositive Net Change MNPRNegative Net Change
biotechnology biotechs medical pharmaceuticals
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.
VSTMNegative Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
by Sundeep Ganoria
Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.
NVOPositive Net Change MRKPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Corcept Submits Application for Another Cushing's Syndrome Drug
by Zacks Equity Research
CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.
BMYPositive Net Change RIGLPositive Net Change CORTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
by Zacks Equity Research
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.
NVSPositive Net Change PTCTNegative Net Change OLMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
by Zacks Equity Research
Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.
PFEPositive Net Change BMRNPositive Net Change SGMOPositive Net Change
biotechs
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why
by Zacks Equity Research
Sales of PBYI's sole-marketed drug, Nerlynx exceeded management's expectations in the third quarter. Also, the acquisition of alisertib holds promise.
RHHBYPositive Net Change PBYIPositive Net Change SPRONegative Net Change IMCRPositive Net Change
biotechs
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
by Sundeep Ganoria
The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.
AZNPositive Net Change JNJPositive Net Change EBSPositive Net Change
biotechs medical pharmaceuticals vaccines
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
by Zacks Equity Research
Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.
JNJPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
by Sundeep Ganoria
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
ALLOPositive Net Change IMCRPositive Net Change DAWNPositive Net Change
biotechs medical pharmaceuticals
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
by Ahan Chakraborty
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.
MESOPositive Net Change KODPositive Net Change MNPRNegative Net Change ARQTPositive Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
by Zacks Equity Research
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.
ADMANegative Net Change STOKPositive Net Change TARSNo Net Change
biotechs
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
by Zacks Equity Research
The European Commission approves Bristol Myers' Opdivo plus Yervoy for first-line treatment of MSI-H or dMMR unresectable or metastatic colorectal cancer.
BMYPositive Net Change SPRONegative Net Change CSTLPositive Net Change IMCRPositive Net Change
biotechs